16
Participants
Start Date
May 31, 2012
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
crizotinib
Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
esomeprazole
Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
Pfizer Investigational Site, Brussels
Lead Sponsor
Pfizer
INDUSTRY